NeoGenomics launches RaDaR ST ctDNA assay for molecular residual disease detection across solid tumor types (ir.neogenomics.com)

• RaDaR ST uses patient-specific, tumor-informed panels for MRD detection.
• Assay achieves LOD95 of 11 ppm and tracks up to 48 tumor variants.
• Medicare approved for initial indications; two more pending reimbursement.

"NeoGenomics (NASDAQ: NEO) has commercially launched RaDaR ST, a tumor-informed ctDNA assay for molecular residual disease (MRD) detection across multiple solid tumors. The assay uses whole-exome sequencing to track up to 48 tumor-specific variants with a limit of detection (LOD95) of 11 ppm. Medicare has approved initial indications; two additional indications are under reimbursement review. The company estimates the MRD market at over $20 billion with 30% annual growth."